Hims & Hers Health Inc. grabbed Wall Street’s attention at the end of the week after an explosive move in late trading changed the tone around one of the market’s most closely watched telehealth names. Shares of Hims & Hers Health (NYSE: HIMS) finished the regular session at $15.74, down 0.88%, before surging to around $22.00 in after-hours trading, a gain of roughly 39.77%, as investors reacted to reports that the company and Novo Nordisk had resolved their recent dispute and could begin working together to sell obesity treatments through the Hims platform.
The late-session move was striking not just because of its size, but because it arrived after a bruising stretch for the stock. Recent market data circulating across finance platforms showed HIMS shares had fallen about 37.8% over the last month and roughly 53.8% over the past year, reflecting how quickly sentiment had deteriorated as regulatory pressure, valuation concerns and analyst target cuts piled up around the name.
At the center of the latest rally is the fast-growing obesity drug market. Bloomberg, citing people familiar with the matter, reported that Wegovy maker Novo Nordisk plans to sell its weight-loss drugs through the Hims & Hers platform after the two sides moved beyond a dispute that had escalated into legal action. That legal clash had become one of the biggest overhangs on Hims stock after Novo sued the company following the launch of a low-cost compounded semaglutide pill, priced at $49 for the first month, before Hims later pulled that product from the market.
The significance of a potential Hims-Novo commercial arrangement is hard to ignore. A tie-up with the company behind Wegovy would give Hims stronger positioning in one of the most lucrative corners of healthcare while also helping address investor fears that the telehealth platform could be boxed out of the branded GLP-1 ecosystem. That said, the rally does not erase the deeper concerns that have been weighing on the stock for weeks.
Those concerns start with regulation. The U.S. Food and Drug Administration said this week that it had issued warning letters to 30 telehealth companies over false or misleading claims involving compounded GLP-1 products. The agency said some firms were implying that compounded products were the same as FDA-approved medicines or were obscuring the true source of the drugs. Compounded products are not FDA-approved, and the FDA has made clear that companies cannot mass-market them as though they were equivalent to branded treatments such as Wegovy, Ozempic, Zepbound, Mounjaro or Saxenda.
That matters because Hims has been one of the most visible public companies exposed to the GLP-1 compounding controversy. Investors have worried that rising FDA scrutiny could limit the company’s ability to market, scale or profit from parts of its weight-loss business the same way it had hoped. The regulatory cloud also helped trigger a wave of analyst target cuts after earnings.
Among the most notable revisions, Barclays lowered its price target on Hims & Hers to $25 from $48 while keeping an Overweight rating. TD Cowen reduced its target to $17 from $20 and maintained a Hold rating. Morgan Stanley also cut its target to $21 from $40 with an Equal Weight rating. The message from Wall Street was fairly consistent: the long-term platform story still has appeal, but near-term regulatory uncertainty and profitability pressure have become harder to ignore.
Even so, Hims’ operating growth has remained impressive. In its latest results, the company reported Q4 revenue of $617.8 million, roughly in line with consensus expectations, while full-year 2025 revenue reached approximately $2.35 billion, up 59% from the prior year. The company also said subscribers grew to more than 2.5 million, up 13% year over year, underscoring that demand across its broader digital health platform is still expanding. Management pointed to continued growth in personalized care, diagnostics, hormone therapies and international initiatives as evidence that the business is diversifying beyond any single category.
There were weaker spots in the report as well, and they added to the pressure on the shares before this after-hours rebound. Hims posted Q4 adjusted earnings of $0.08 per share, below the $0.19 consensus estimate cited in analyst commentary. Profitability metrics also moved in the wrong direction, with gross margin trending lower versus earlier periods and investors questioning whether the company’s heavier investments are coming too quickly for the current margin structure.
The company’s 2026 outlook further fueled that debate. Hims told investors it expects full-year 2026 revenue in the range of $2.7 billion to $2.9 billion and adjusted EBITDA of $300 million to $375 million. While the top-line outlook suggested the growth engine is still running, some analysts argued that the EBITDA guide showed margin pressure from investment spending and operational complexity, especially as Hims pushes deeper into new categories and geographies.
Management, however, has continued to talk in ambitious terms. The company has previously highlighted a long-range target of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. It has also stressed that its consumer-first model, digital platform, subscription engine and expanding care categories give it a foundation to compete well beyond hair loss and sexual health, which were once the core pillars of the Hims brand.
Recent insider activity added another layer to the story. Disclosures showed five insider transactions in late February, including one stock sale worth $70,741.71 by Chief Legal Officer Soleil Boughton, plus four stock awards totaling 1,843,544 shares granted to executives. The filings did not point to unusual selling pressure, but they arrived at a time when traders were already dissecting every detail tied to confidence in the company’s outlook.
For now, Hims & Hers remains one of the market’s more polarizing healthcare growth names. Bulls see a rapidly scaling digital health platform with millions of subscribers, expanding international reach and a possible opening to distribute branded obesity drugs. Bears see a company facing hard regulatory questions, shrinking margins, lowered analyst targets and a business model that still has to prove it can grow responsibly under tighter oversight. Friday’s after-hours surge made one point clear: sentiment around HIMS can turn fast, and every headline tied to GLP-1 access, FDA enforcement and strategic partnerships is likely to keep driving outsized moves in the stock.
For investors watching the next chapter, the biggest focus now shifts to confirmation of the reported Novo Nordisk arrangement, further clarity on FDA enforcement risk and whether Hims can translate its impressive subscriber scale into steadier profitability. Until then, HIMS looks set to remain a high-volatility healthcare stock with both major upside intrigue and very real execution risk.
You May Also Like
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
